India poised to lead pharma innovation

Regulatory evolution and streamlined pathways for innovative molecules aligned with global standards will strengthen confidence among innovators

- NK GANGULY

WHEN HIV/AIDS THREATENED to become a generational catastrophe across the developing world in the early 2000s, it was India that broke the economic barrier producing antiretrovirals at a fraction of the prevailing cost and putting lifesaving treatment within reach of millions. That moment captured something essential: India’s ability to harness scientific capability and manufacturing scale in service of a larger human purpose. Supplying over 20% of global generic medicines by volume today, India’s pharmaceutical industry is one of the most consequential of our era and that foundation is the launchpad for an even more ambitious chapter now beginning to take shape.

The economic logic is compelling. A patented first-in-class medicine commands significantly higher margins and longer market exclusivity than a generic equivalent. India’s pharma exports are close to $30 billion, a remarkable feat; yet its share of global new molecular entity approval Is remains below 2%. The gap between contribution and credit is wide and closing it represents both a strategic imperative and a substantial economic opportunity.

Nations that invested deliberately in their biopharma ecosystems, building clinical trial-friendly environments, robust IP frameworks, and targeted innovation incentives have demonstrated what focused ambition can achieve. India's structural advantages—a vast and diverse patient population, world-class scientific talent, and significant cost efficiencies—represent a far stronger foundation to build upon.